George Moose, an official associated with the U.S. Institute of Peace, said it is not a federal agency or in a federal building. The Department of Government Efficiency (DOGE) said its staffers, along with acting U.S. Institute of Peace President Kenneth Jackson, entered the institute’s headquarters in Washington with police amid what it described as
Trump earlier called for the impeachment of a judge who blocked the president’s proclamation seeking to deport alleged members of a Venezuelan gang. Chief Justice John Roberts issued a rare public statement on March 18, appearing to counter President Donald Trump’s call to impeach a federal judge who blocked deportations of members of a Venezuelan
FBI Director Kash Patel said alleged MS-13 leader Francisco Javier Roman-Bardales, of the FBI's most wanted fugitives, is being extradited to the U.S.
Washington — Chief Justice John Roberts issued a rare statement Tuesday defending federal judges who have issued decisions against the Trump administration, saying that “impeachment is not an appropriate response to disagreement” with a court’s decision. “For more than two centuries, it has been established that impeachment is not an appropriate response to disagreement concerning
Gary Shapley and Joseph Ziegler tapped as senior advisers for IRS reform Supervisory IRS Special Agent Gary Shapley and IRS Criminal Investigator Joseph Ziegler at a House Oversight Committee hearing (Drew Angerer/Getty Images) The two IRS investigators who exposed details of the investigation into former first son Hunter Biden have been promoted to senior roles
Two of the judges seemed critical of attempts to temporarily maintain lower court decisions keeping the two agency heads in their positions. A three-judge panel on the U.S. Court of Appeals for the District of Columbia Circuit seemed inclined on March 18 to allow President Donald Trump’s removals of two agency heads who alleged that
The "Delinking Revenue from Unfair Gouging (DRUG) Act" was unveiled by a group of bipartisan lawmakers Tuesday, aimed at reforming the incentive structure for Pharmacy Benefit Managers so that they are not encouraged to promote high-cost drugs.